Materiały źródłowe

• #1 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  Rhabdomyosarcoma is a rare type of soft tissue cancer but the most common type of soft tissue sarcoma in children. […] We are now applying this approach to all pediatric solid tumors to be more effective at preventing recurrence and improving outcomes. […] We need to eliminate all the tumor cells (each clone) to achieve a cure. […] We will employ chemotherapy using targeted agents (e.g., EGFR inhibitors) and antibody-drug conjugates and even consider CAR T-cells. […] We were pleased to see EGFR as a potential target within our data because there is a deep and long-standing track record of targeting that receptor. […] So, it seemed natural to test EGFR inhibitors against rhabdomyosarcoma. […] The results were exciting, but we still have a lot of work to do before we’re ready to test EGFR inhibitors in patients.

• #2 Rhabdomyosarcoma – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/rhabdomyosarcoma/symptoms-causes/syc-20390962

  There is no way to prevent rhabdomyosarcoma. […] Factors that may increase the risk of rhabdomyosarcoma include: […] Rhabdomyosarcoma most often happens to children younger than 10. […] Rarely, rhabdomyosarcoma has been linked to genetic syndromes that are passed from parents to children.

• #3 Rhabdomyosarcoma Causes, Risk Factors, and Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/rhabdomyosarcoma/causes-risks-prevention.html

  There are no proven lifestyle-related or environmental causes of RMS, so at this time there is no way to protect against these cancers. […] Can Rhabdomyosarcoma Be Prevented?

• #4 Can Rhabdomyosarcoma Be Prevented? | American Cancer Society

  https://www.cancer.org/cancer/types/rhabdomyosarcoma/causes-risks-prevention/prevention.html

  The risk of many cancers that typically occur in adults can be reduced with certain lifestyle changes (such as staying at a healthy weight or quitting smoking), but at this time there are no known ways to prevent most cancers in children. […] The only known risk factors for rhabdomyosarcoma (RMS) age, sex, and certain inherited conditions cant be changed. There are no proven lifestyle-related or environmental causes of RMS, so at this time there is no known way to protect against these cancers.

• #5 Rhabdomyosarcoma primary prevention – wikidoc

  https://www.wikidoc.org/index.php/Rhabdomyosarcoma_primary_prevention

  There are no primary preventive measures available for rhabdomyosarcoma. […] There are no primary preventive measures available for childhood cancers such as rhabdomyosarcoma.

• #6 Pediatric Rhabdomyosarcoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/988803-overview

  No preventive measures are known for childhood cancers.

• #7 Can Rhabdomyosarcoma Be Prevented? | American Cancer Society

  https://www.cancer.org/cancer/types/rhabdomyosarcoma/causes-risks-prevention/prevention.html

  The risk of many cancers that typically occur in adults can be reduced with certain lifestyle changes (such as staying at a healthy weight or quitting smoking), but at this time there are no known ways to prevent most cancers in children. […] The only known risk factors for rhabdomyosarcoma (RMS) age, sex, and certain inherited conditions cant be changed. There are no proven lifestyle-related or environmental causes of RMS, so at this time there is no known way to protect against these cancers.

• #8 Can Rhabdomyosarcoma Be Prevented? | American Cancer Society

  https://www.cancer.org/cancer/types/rhabdomyosarcoma/causes-risks-prevention/prevention.html

  The risk of many cancers that typically occur in adults can be reduced with certain lifestyle changes (such as staying at a healthy weight or quitting smoking), but at this time there are no known ways to prevent most cancers in children. […] The only known risk factors for rhabdomyosarcoma (RMS) age, sex, and certain inherited conditions cant be changed. There are no proven lifestyle-related or environmental causes of RMS, so at this time there is no known way to protect against these cancers.

• #9 Rhabdomyosarcoma Treatment in Mumbai, India | Nanavati Max Hospital

  https://www.nanavatimaxhospital.org/our-specialities/cancer-centre/conditions-treatments/rhabdomyosarcoma

  Because the exact cause of the tumor is unknown, there aren’t any measures to prevent rhabdomyosarcoma. Lifestyle changes or environmental modifications do not prevent rhabdomyosarcoma. […] Even after successfully completing the treatment, follow-up should be regularly done to prevent the onset of secondary tumors. CT scans and MRI scans are usually advised to detect the recurrence of the tumor. Physiotherapy can help the patient to regain strength.

• #10 Rhabdomyosarcomas | EBSCO Research Starters

  https://www.ebsco.com/research-starters/health-and-medicine/rhabdomyosarcomas

  There are no known environmental or lifestyle risk factors associated with its development, although certain inherited conditions can increase susceptibility. […] While there are no preventive measures for rhabdomyosarcoma, advances in treatment have improved outcomes for affected children. […] There is no way to prevent rhabdomyosarcoma.

• #11 Rhabdomyosarcoma Treatment in Delhi, India | Symptoms & Causes

  https://www.blkmaxhospital.com/our-specialities/sarcoma-and-bone-cancer-program/conditions-treatments/rhabdomyosarcoma

  As doctors and medical experts do not know why and how a child gets rhabdomyosarcoma, there is no way to prevent this cancer or reduce the risk.

• #12 Rhabdomyosarcoma | Baptist Health Miami Cancer Institute

  https://baptisthealth.net/services/cancer-care/miami-cancer-institute/our-approach/pediatric-cancers/rhabdomyosarcoma

  Because most known risk factors are not preventable, there are no recommended preventive measures. […] Some children with risk factors may benefit from genetic testing to determine specific risk.

• #13 Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma | BCM

  https://www.bcm.edu/news/cancer-predisposition-variants-associated-with-adverse-outcomes-in-rhabdomyosarcoma

  Germline cancer-predisposition variants (CPVs) can be helpful in predicting risk in some pediatric cancers. […] The results of our study support germline testing for cancer-predisposition variants among children with rhabdomyosarcoma, which could aid in early clinical surveillance strategies for patients and cascade testing of family members, Lupo said.

• #14 Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma | BCM

  https://www.bcm.edu/news/cancer-predisposition-variants-associated-with-adverse-outcomes-in-rhabdomyosarcoma

  Germline cancer-predisposition variants (CPVs) can be helpful in predicting risk in some pediatric cancers. […] The results of our study support germline testing for cancer-predisposition variants among children with rhabdomyosarcoma, which could aid in early clinical surveillance strategies for patients and cascade testing of family members, Lupo said.

• #15 Rhabdomyosarcoma – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/rhabdomyosarcoma/symptoms-causes/syc-20390962

  There is no way to prevent rhabdomyosarcoma. […] Factors that may increase the risk of rhabdomyosarcoma include: […] Rhabdomyosarcoma most often happens to children younger than 10. […] Rarely, rhabdomyosarcoma has been linked to genetic syndromes that are passed from parents to children.

• #16 Rhabdomyosarcoma | 5-Minute Pediatric Consult

  https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617335/all/Rhabdomyosarcoma?q=antiemetics

  No standard approach because usually sporadic […] Avoidance of radiation in patients with known predisposing syndromes (e.g., Li-Fraumeni syndrome)

• #17 Rhabdomyosarcoma | 5-Minute Pediatric Consult

  https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617335/all/Rhabdomyosarcoma?q=Cell+Germ+Tumors

  No standard approach because usually sporadic. […] Avoidance of radiation in patients with known predisposing syndromes (e.g., Li-Fraumeni syndrome).

• #18 Germline and Somatic Genetic Landscape of Pediatric Rhabdomyosarcoma – EGA European Genome-Phenome Archive

  https://ega-archive.org/studies/phs002304

  Dynamic approaches that integrate population-based research and molecular biology are needed to explain the mechanisms underlying pediatric rhabdomyosarcoma (RMS) and to determine novel prevention strategies. […] Therefore, a major gap in our understanding of the role of cancer predisposition in pediatric RMS that limit translational impact is there have been no population-based assessments to determine the true impact of these mutations on pediatric RMS, which limits clinical sequencing guidelines and surveillance protocols in these children.

• #19 Rhabdomyosarcoma Treatment in Mumbai, India | Nanavati Max Hospital

  https://www.nanavatimaxhospital.org/our-specialities/cancer-centre/conditions-treatments/rhabdomyosarcoma

  Because the exact cause of the tumor is unknown, there aren’t any measures to prevent rhabdomyosarcoma. Lifestyle changes or environmental modifications do not prevent rhabdomyosarcoma. […] Even after successfully completing the treatment, follow-up should be regularly done to prevent the onset of secondary tumors. CT scans and MRI scans are usually advised to detect the recurrence of the tumor. Physiotherapy can help the patient to regain strength.

• #20 Rhabdomyosarcoma Treatment in Mumbai, India | Nanavati Max Hospital

  https://www.nanavatimaxhospital.org/our-specialities/cancer-centre/conditions-treatments/rhabdomyosarcoma

  Because the exact cause of the tumor is unknown, there aren’t any measures to prevent rhabdomyosarcoma. Lifestyle changes or environmental modifications do not prevent rhabdomyosarcoma. […] Even after successfully completing the treatment, follow-up should be regularly done to prevent the onset of secondary tumors. CT scans and MRI scans are usually advised to detect the recurrence of the tumor. Physiotherapy can help the patient to regain strength.

• #21 Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence – St. Jude Children’s Research Hospital

  https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/egfr-inhibitors-may-prevent-rhabdomyosarcoma-recurrence.html

  Rhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Childrens Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence. They found that these cells mirror an early developmental state that responds to EGFR inhibitors. […] The researchers wanted to better understand the cells that give rise to recurrent rhabdomyosarcoma to identify new treatments to prevent the cancer from returning after therapy. […] The team found that this population of cells depends on epidermal growth factor receptor (EGFR) signaling and is sensitive to EGFR inhibitors. EGFR inhibitors are a type of targeted therapy used to treat cancers with mutations in the EGFR gene, such as lung cancer in adults. The findings support a clinical trial strategy that includes EGFR inhibitors in rhabdomyosarcoma treatment.

• #22 Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence – St. Jude Children’s Research Hospital

  https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/egfr-inhibitors-may-prevent-rhabdomyosarcoma-recurrence.html

  Rhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Childrens Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence. They found that these cells mirror an early developmental state that responds to EGFR inhibitors. […] The researchers wanted to better understand the cells that give rise to recurrent rhabdomyosarcoma to identify new treatments to prevent the cancer from returning after therapy. […] The team found that this population of cells depends on epidermal growth factor receptor (EGFR) signaling and is sensitive to EGFR inhibitors. EGFR inhibitors are a type of targeted therapy used to treat cancers with mutations in the EGFR gene, such as lung cancer in adults. The findings support a clinical trial strategy that includes EGFR inhibitors in rhabdomyosarcoma treatment.

• #23 Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence – St. Jude Children’s Research Hospital

  https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/egfr-inhibitors-may-prevent-rhabdomyosarcoma-recurrence.html

  Rhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Childrens Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence. They found that these cells mirror an early developmental state that responds to EGFR inhibitors. […] The researchers wanted to better understand the cells that give rise to recurrent rhabdomyosarcoma to identify new treatments to prevent the cancer from returning after therapy. […] The team found that this population of cells depends on epidermal growth factor receptor (EGFR) signaling and is sensitive to EGFR inhibitors. EGFR inhibitors are a type of targeted therapy used to treat cancers with mutations in the EGFR gene, such as lung cancer in adults. The findings support a clinical trial strategy that includes EGFR inhibitors in rhabdomyosarcoma treatment.

• #24 Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence – St. Jude Children’s Research Hospital

  https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/egfr-inhibitors-may-prevent-rhabdomyosarcoma-recurrence.html

  We have a proof of concept that if you target those rare cells that persist with an EGFR inhibitor and combine that with chemotherapy you get a much better outcome because you’re treating the entire tumor. This reflects a different way of thinking about therapy that isn’t focused just on initial response.

• #25 Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence – St. Jude Children’s Research Hospital

  https://www.stjude.org/media-resources/news-releases/2022-medicine-science-news/egfr-inhibitors-may-prevent-rhabdomyosarcoma-recurrence.html

  We have a proof of concept that if you target those rare cells that persist with an EGFR inhibitor and combine that with chemotherapy you get a much better outcome because you’re treating the entire tumor. This reflects a different way of thinking about therapy that isn’t focused just on initial response.

• #26 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  In addition to the EGFR inhibitors, we are also testing antibody-drug conjugates and hope to explore the possibility of developing a CAR T cell for this target. […] Now that we know the molecular and cellular mechanisms of recurrence, we can do a better job of killing all the tumor cells and preventing recurrence.

• #27 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  Rhabdomyosarcoma is a rare type of soft tissue cancer but the most common type of soft tissue sarcoma in children. […] We are now applying this approach to all pediatric solid tumors to be more effective at preventing recurrence and improving outcomes. […] We need to eliminate all the tumor cells (each clone) to achieve a cure. […] We will employ chemotherapy using targeted agents (e.g., EGFR inhibitors) and antibody-drug conjugates and even consider CAR T-cells. […] We were pleased to see EGFR as a potential target within our data because there is a deep and long-standing track record of targeting that receptor. […] So, it seemed natural to test EGFR inhibitors against rhabdomyosarcoma. […] The results were exciting, but we still have a lot of work to do before we’re ready to test EGFR inhibitors in patients.

• #28 Pediatric Rhabdomyosarcoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988803-followup

  Trimethoprim-sulfamethoxazole: Prophylaxis against pneumocystic pneumonia should continue until 6 months after the end of chemotherapy. […] Fluconazole: Systemic fungal prophylaxis is not necessary. […] Clotrimazole: Prophylactic therapy for thrush may be discontinued after chemotherapy is completed. […] Chlorhexidine mouth rinse: Prophylaxis against gingivitis and other mouth infections may be discontinued after chemotherapy is completed.

• #29 Pediatric Rhabdomyosarcoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988803-followup

  Trimethoprim-sulfamethoxazole: Prophylaxis against pneumocystic pneumonia should continue until 6 months after the end of chemotherapy. […] Fluconazole: Systemic fungal prophylaxis is not necessary. […] Clotrimazole: Prophylactic therapy for thrush may be discontinued after chemotherapy is completed. […] Chlorhexidine mouth rinse: Prophylaxis against gingivitis and other mouth infections may be discontinued after chemotherapy is completed.

• #30 Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12766-w

  Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. […] Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. […] Currently, granulocyte-colony stimulating factor (G-CSF) drugs have been recognized as one of the most commonly used regimens for prophylaxis of chemotherapy-induced FN and neutropenia, however, only a few studies have focused on the efficacy and safety of G-CSF drugs in pediatric and adolescent patients. […] On the basis of the above information, we conducted this pilot, single-arm study aimed to explore the efficacy and safety of mecapegfilgrastim for the prophylaxis of FN in pediatric and adolescent patients with RMS or ES. […] Patients who are treated with the VDC regimen should be monitored with caution even after receiving long-acting rhG-CSF drugs. […] Further randomized studies with large sample sizes and secondary prophylaxis data are warranted.

• #31 Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12766-w

  Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. […] Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. […] Currently, granulocyte-colony stimulating factor (G-CSF) drugs have been recognized as one of the most commonly used regimens for prophylaxis of chemotherapy-induced FN and neutropenia, however, only a few studies have focused on the efficacy and safety of G-CSF drugs in pediatric and adolescent patients. […] On the basis of the above information, we conducted this pilot, single-arm study aimed to explore the efficacy and safety of mecapegfilgrastim for the prophylaxis of FN in pediatric and adolescent patients with RMS or ES. […] Patients who are treated with the VDC regimen should be monitored with caution even after receiving long-acting rhG-CSF drugs. […] Further randomized studies with large sample sizes and secondary prophylaxis data are warranted.

• #32 Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12766-w

  Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. […] Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. […] Currently, granulocyte-colony stimulating factor (G-CSF) drugs have been recognized as one of the most commonly used regimens for prophylaxis of chemotherapy-induced FN and neutropenia, however, only a few studies have focused on the efficacy and safety of G-CSF drugs in pediatric and adolescent patients. […] On the basis of the above information, we conducted this pilot, single-arm study aimed to explore the efficacy and safety of mecapegfilgrastim for the prophylaxis of FN in pediatric and adolescent patients with RMS or ES. […] Patients who are treated with the VDC regimen should be monitored with caution even after receiving long-acting rhG-CSF drugs. […] Further randomized studies with large sample sizes and secondary prophylaxis data are warranted.

• #33 Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12766-w

  Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. […] Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. […] Currently, granulocyte-colony stimulating factor (G-CSF) drugs have been recognized as one of the most commonly used regimens for prophylaxis of chemotherapy-induced FN and neutropenia, however, only a few studies have focused on the efficacy and safety of G-CSF drugs in pediatric and adolescent patients. […] On the basis of the above information, we conducted this pilot, single-arm study aimed to explore the efficacy and safety of mecapegfilgrastim for the prophylaxis of FN in pediatric and adolescent patients with RMS or ES. […] Patients who are treated with the VDC regimen should be monitored with caution even after receiving long-acting rhG-CSF drugs. […] Further randomized studies with large sample sizes and secondary prophylaxis data are warranted.

• #34

  https://journals.lww.com/amjclinicaloncology/abstract/1983/08000/childhood_rhabdomyosarcoma_with_meningeal.2.aspx

  RESULTS ACHIEVED IN TWO CONSECUTIVE SERIES of children with rhabdomyosarcoma (RMSA) of the head and neck area, presenting with meningeal involvement, are compared. […] The second series consisted of 11 children who, besides local radiotherapy and polichemotherapy, received brain radiotherapy (30 Gy) and intrathecal (I.T.) methotrexate (MTX) as central nervous system (CNS) prophylaxis from 1978 to 1980. […] This observation and the higher doses of radiotherapy delivered to the primary tumor in the second series prevent the conclusion that the improved results are attributable entirely to the addition of CNS prophylaxis.

• #35

  https://journals.lww.com/amjclinicaloncology/abstract/1983/08000/childhood_rhabdomyosarcoma_with_meningeal.2.aspx

  RESULTS ACHIEVED IN TWO CONSECUTIVE SERIES of children with rhabdomyosarcoma (RMSA) of the head and neck area, presenting with meningeal involvement, are compared. […] The second series consisted of 11 children who, besides local radiotherapy and polichemotherapy, received brain radiotherapy (30 Gy) and intrathecal (I.T.) methotrexate (MTX) as central nervous system (CNS) prophylaxis from 1978 to 1980. […] This observation and the higher doses of radiotherapy delivered to the primary tumor in the second series prevent the conclusion that the improved results are attributable entirely to the addition of CNS prophylaxis.

• #36 Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension – PubMed

  https://pubmed.ncbi.nlm.nih.gov/2230872/

  A series of 15 consecutive children with head and neck nonorbital rhabdomyosarcoma (RMSA) with meningeal extension were prospectively treated with chemotherapy consisting of Adriamycin (doxorubicin; Adria Laboratory, Columbus, OH) (ADM), vincristine (VCR), cyclophosphamide (CPM), and dactinomycin (DACT) followed by radiotherapy (60 Gy) to the primary tumor volume, along with intrathecal methotrexate (IT MTX). […] It is concluded that CNS prophylaxis with radiotherapy is questionable in the management of childhood RMSA with meningeal extension.

• #37 Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension – PubMed

  https://pubmed.ncbi.nlm.nih.gov/2230872/

  A series of 15 consecutive children with head and neck nonorbital rhabdomyosarcoma (RMSA) with meningeal extension were prospectively treated with chemotherapy consisting of Adriamycin (doxorubicin; Adria Laboratory, Columbus, OH) (ADM), vincristine (VCR), cyclophosphamide (CPM), and dactinomycin (DACT) followed by radiotherapy (60 Gy) to the primary tumor volume, along with intrathecal methotrexate (IT MTX). […] It is concluded that CNS prophylaxis with radiotherapy is questionable in the management of childhood RMSA with meningeal extension.

• #38 Germline and Somatic Genetic Landscape of Pediatric Rhabdomyosarcoma – EGA European Genome-Phenome Archive

  https://ega-archive.org/studies/phs002304

  Dynamic approaches that integrate population-based research and molecular biology are needed to explain the mechanisms underlying pediatric rhabdomyosarcoma (RMS) and to determine novel prevention strategies. […] Therefore, a major gap in our understanding of the role of cancer predisposition in pediatric RMS that limit translational impact is there have been no population-based assessments to determine the true impact of these mutations on pediatric RMS, which limits clinical sequencing guidelines and surveillance protocols in these children.

• #39 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  Rhabdomyosarcoma is a rare type of soft tissue cancer but the most common type of soft tissue sarcoma in children. […] We are now applying this approach to all pediatric solid tumors to be more effective at preventing recurrence and improving outcomes. […] We need to eliminate all the tumor cells (each clone) to achieve a cure. […] We will employ chemotherapy using targeted agents (e.g., EGFR inhibitors) and antibody-drug conjugates and even consider CAR T-cells. […] We were pleased to see EGFR as a potential target within our data because there is a deep and long-standing track record of targeting that receptor. […] So, it seemed natural to test EGFR inhibitors against rhabdomyosarcoma. […] The results were exciting, but we still have a lot of work to do before we’re ready to test EGFR inhibitors in patients.

• #40 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  Rhabdomyosarcoma is a rare type of soft tissue cancer but the most common type of soft tissue sarcoma in children. […] We are now applying this approach to all pediatric solid tumors to be more effective at preventing recurrence and improving outcomes. […] We need to eliminate all the tumor cells (each clone) to achieve a cure. […] We will employ chemotherapy using targeted agents (e.g., EGFR inhibitors) and antibody-drug conjugates and even consider CAR T-cells. […] We were pleased to see EGFR as a potential target within our data because there is a deep and long-standing track record of targeting that receptor. […] So, it seemed natural to test EGFR inhibitors against rhabdomyosarcoma. […] The results were exciting, but we still have a lot of work to do before we’re ready to test EGFR inhibitors in patients.

• #41 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  Rhabdomyosarcoma is a rare type of soft tissue cancer but the most common type of soft tissue sarcoma in children. […] We are now applying this approach to all pediatric solid tumors to be more effective at preventing recurrence and improving outcomes. […] We need to eliminate all the tumor cells (each clone) to achieve a cure. […] We will employ chemotherapy using targeted agents (e.g., EGFR inhibitors) and antibody-drug conjugates and even consider CAR T-cells. […] We were pleased to see EGFR as a potential target within our data because there is a deep and long-standing track record of targeting that receptor. […] So, it seemed natural to test EGFR inhibitors against rhabdomyosarcoma. […] The results were exciting, but we still have a lot of work to do before we’re ready to test EGFR inhibitors in patients.

• #42 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  In addition to the EGFR inhibitors, we are also testing antibody-drug conjugates and hope to explore the possibility of developing a CAR T cell for this target. […] Now that we know the molecular and cellular mechanisms of recurrence, we can do a better job of killing all the tumor cells and preventing recurrence.

• #43 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20220512/Researchers-Identify-Potential-Target-for-Rhabdomyosarcoma-Recurrence-Prevention.aspx

  In addition to the EGFR inhibitors, we are also testing antibody-drug conjugates and hope to explore the possibility of developing a CAR T cell for this target. […] Now that we know the molecular and cellular mechanisms of recurrence, we can do a better job of killing all the tumor cells and preventing recurrence.

Zobacz więcej